Boston Scientific Corporation vs Sirius XM Holdings Inc — how do they compare? Boston Scientific Corporation trades at $51.58 (market cap $74.19B), while Sirius XM Holdings Inc trades at $28.29 (market cap $9.70B). The key difference: Boston Scientific Corporation is far larger — about 7.6× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SIRI | |
|---|---|---|
Market Cap | $74.19B | $9.70B |
Sector | Health | Media |
52-Week High | $108.14 | $32.59 |
52-Week Low | $42.63 | $19.92 |
Enterprise Value | $86.27B | $18.98B |
Dividend Yield | — | 3.75% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Sirius XM Holdings (SIRI) trades at $28.275, down 1.75% today, with a bearish technical signal and mixed earnings history including a Q2 2026 miss. The company maintains stable cash flow, with Q2 revenue up 1% year-over-year and raised 2026 guidance. Valuation appears attractive with a P/E of 11.56 and P/B below 1, while a $0.27 dividend provides income support.
Outlook: SIRI offers value with solid fundamentals and shareholder returns, but faces competitive pressures and subscriber volatility. Risks include high debt and market sentiment shifts. Analysts see 17% upside to the $33.17 consensus target, supporting a cautious buy view for income-focused investors.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →